Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Enzon Pharmaceuticals Inc (ENZN)

Enzon Pharmaceuticals Inc (ENZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,567
  • Shares Outstanding, K 74,220
  • Annual Sales, $ 0 K
  • Annual Income, $ 1,370 K
  • 60-Month Beta 0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.28
Trade ENZN with:
  • Price/Earnings ttm 7.50
  • Earnings Per Share ttm 0.01
  • Most Recent Earnings $0.01 on 03/20/24
  • Latest Earnings Date 05/03/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.240 on 09/30/19
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0647 +15.92%
on 04/15/24
0.0997 -24.77%
on 04/09/24
+0.0100 (+15.38%)
since 04/03/24
3-Month
0.0600 +25.00%
on 04/01/24
0.1050 -28.57%
on 02/05/24
-0.0300 (-28.57%)
since 02/02/24
52-Week
0.0600 +25.00%
on 04/01/24
0.2194 -65.82%
on 06/16/23
-0.1450 (-65.91%)
since 05/02/23

Most Recent Stories

More News
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO

CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s...

ENZN : 0.0750 (unch)
Enzon Pharmaceuticals Announces Results of Rights Offering

Looking to Next Step – Acquisition Opportunities

ENZN : 0.0750 (unch)
Enzon Pharmaceuticals Announces Key Dates for Rights Offering

CRANFORD, N.J., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced today the record date and expected subscription period for its previously-announced...

ENZN : 0.0750 (unch)
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting

CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual...

ENZN : 0.0750 (unch)
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders

CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved...

ENZN : 0.0750 (unch)
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value

CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax...

ENZN : 0.0750 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular...

See More

Key Turning Points

3rd Resistance Point 0.0750
2nd Resistance Point 0.0750
1st Resistance Point 0.0750
Last Price 0.0750
1st Support Level 0.0750
2nd Support Level 0.0750
3rd Support Level 0.0750

See More

52-Week High 0.2194
Fibonacci 61.8% 0.1585
Fibonacci 50% 0.1397
Fibonacci 38.2% 0.1209
Last Price 0.0750
52-Week Low 0.0600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar